Global Renal Anemia Therapeutics

Renal Anemia Therapeutics Comprehensive Study by Type (DS-1093, EPO-018B, FG-2216, JTZ-951, MDGN-201), Application (Hospital, Research Center, Clinic), Mode of Administration (Oral, Parenteral) Players and Region - Global Market Outlook to 2024

Renal Anemia Therapeutics Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Renal Anemia Therapeutics Market Scope
Renal Anemia is a medical condition that is conducted by the body. It is the condition where the body is producing lesser red blood cells than normal this situation led in the results in a decline in oxygen delivery to vital tissues and organs. This disease is referred to as anemia that occurs due to renal dysfunction or chronic kidney disease. This condition is diagnosed by using intravenous or oral supplements of iron and many more prescribed drugs. A high prevalence of chronic diseases majorly in geriatric people is driving the market.

The market study is being classified by Type (DS-1093, EPO-018B, FG-2216, JTZ-951 and MDGN-201), by Application (Hospital, Research Center and Clinic) and major geographies with country level break-up.

Research Analyst at AMA predicts that Global Players will contribute to the maximum growth of Global Renal Anemia Therapeutics market throughout the predicted period.

Bayer AG (Germany), BIOCAD (Russia), CCM Duopharma Biotech Berhad (Malaysia), Chong Kun Dang Pharmaceutical Corp.(South Korea), Daiichi Sankyo Company, Limited (Japan), Dong-A Socio Group (South Korea), Dr. Reddy's Laboratories (India), Eli Lilly and Company (United States), FibroGen, Inc (United States) and GlaxoSmithKline Plc (United Kingdom) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Intas Pharmaceuticals Ltd. (India), JCR Pharmaceuticals Co., Ltd. (Japan) and Jiangsu Hansoh Pharmaceutical Co., Ltd.(China).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Renal Anemia Therapeutics market by Type, Application and Region.

On the basis of geography, the market of Renal Anemia Therapeutics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

In Dec 2018, AstraZeneca announced that its partner FibroGen (China) Medical Technology Development Co., Ltd. (FibroGen China) has now received formal marketing authorisation from the National Medical Products Administration (NMPA) for roxadustat, a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) and new oral treatment for patients with anaemia caused by chronic kidney disease (CKD) that are on dialysis. The medicine can be prescribed to patients who use haemodialysis or peritoneal dialysis.


Market Trend
  • Increasing Use of Epoetin alfa Drugs for Treating Anemia in CKD Patients

Market Drivers
  • Growing Prevalence of Chronic Kidney Disease in Developing Countries
  • Rising Number of Renal Disease Patients

Opportunities
  • Potential Market Growth in Countries with the Highest Rate of Degenerative Diseases Such As Diabetes, High Blood Pressure, Glomerulonephritis, etc.
  • Increasing Affordability and Healthcare Access in Developing Countries

Restraints
  • Fear of Late Complications and Reimbursement Issues

Challenges
  • Side-Effects of Oral Administration


Key Target Audience
Healthcare Industry, Government Bodies and Associations, Medicine Manufacturers, Medicine Raw Material Suppliers, Research Companies and Potential Investors

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase

Report Objectives / Segmentation Covered

By Type
  • DS-1093
  • EPO-018B
  • FG-2216
  • JTZ-951
  • MDGN-201
By Application
  • Hospital
  • Research Center
  • Clinic
By Mode of Administration
  • Oral
  • Parenteral

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Prevalence of Chronic Kidney Disease in Developing Countries
      • 3.2.2. Rising Number of Renal Disease Patients
    • 3.3. Market Challenges
      • 3.3.1. Side-Effects of Oral Administration
    • 3.4. Market Trends
      • 3.4.1. Increasing Use of Epoetin alfa Drugs for Treating Anemia in CKD Patients
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Renal Anemia Therapeutics, by Type, Application, Mode of Administration and Region (value, volume and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Renal Anemia Therapeutics (Value)
      • 5.2.1. Global Renal Anemia Therapeutics by: Type (Value)
        • 5.2.1.1. DS-1093
        • 5.2.1.2. EPO-018B
        • 5.2.1.3. FG-2216
        • 5.2.1.4. JTZ-951
        • 5.2.1.5. MDGN-201
      • 5.2.2. Global Renal Anemia Therapeutics by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Research Center
        • 5.2.2.3. Clinic
      • 5.2.3. Global Renal Anemia Therapeutics by: Mode of Administration (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Parenteral
      • 5.2.4. Global Renal Anemia Therapeutics Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Renal Anemia Therapeutics (Volume)
      • 5.3.1. Global Renal Anemia Therapeutics by: Type (Volume)
        • 5.3.1.1. DS-1093
        • 5.3.1.2. EPO-018B
        • 5.3.1.3. FG-2216
        • 5.3.1.4. JTZ-951
        • 5.3.1.5. MDGN-201
      • 5.3.2. Global Renal Anemia Therapeutics by: Application (Volume)
        • 5.3.2.1. Hospital
        • 5.3.2.2. Research Center
        • 5.3.2.3. Clinic
      • 5.3.3. Global Renal Anemia Therapeutics by: Mode of Administration (Volume)
        • 5.3.3.1. Oral
        • 5.3.3.2. Parenteral
      • 5.3.4. Global Renal Anemia Therapeutics Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Renal Anemia Therapeutics (Price)
      • 5.4.1. Global Renal Anemia Therapeutics by: Type (Price)
  • 6. Renal Anemia Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bayer AG (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. BIOCAD (Russia)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. CCM Duopharma Biotech Berhad (Malaysia)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Chong Kun Dang Pharmaceutical Corp.(South Korea)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Daiichi Sankyo Company, Limited (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Dong-A Socio Group (South Korea)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Dr. Reddy's Laboratories (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Eli Lilly and Company (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. FibroGen, Inc (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. GlaxoSmithKline Plc (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Renal Anemia Therapeutics Sale, by Type, Application, Mode of Administration and Region (value, volume and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Renal Anemia Therapeutics (Value)
      • 7.2.1. Global Renal Anemia Therapeutics by: Type (Value)
        • 7.2.1.1. DS-1093
        • 7.2.1.2. EPO-018B
        • 7.2.1.3. FG-2216
        • 7.2.1.4. JTZ-951
        • 7.2.1.5. MDGN-201
      • 7.2.2. Global Renal Anemia Therapeutics by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Research Center
        • 7.2.2.3. Clinic
      • 7.2.3. Global Renal Anemia Therapeutics by: Mode of Administration (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Parenteral
      • 7.2.4. Global Renal Anemia Therapeutics Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Renal Anemia Therapeutics (Volume)
      • 7.3.1. Global Renal Anemia Therapeutics by: Type (Volume)
        • 7.3.1.1. DS-1093
        • 7.3.1.2. EPO-018B
        • 7.3.1.3. FG-2216
        • 7.3.1.4. JTZ-951
        • 7.3.1.5. MDGN-201
      • 7.3.2. Global Renal Anemia Therapeutics by: Application (Volume)
        • 7.3.2.1. Hospital
        • 7.3.2.2. Research Center
        • 7.3.2.3. Clinic
      • 7.3.3. Global Renal Anemia Therapeutics by: Mode of Administration (Volume)
        • 7.3.3.1. Oral
        • 7.3.3.2. Parenteral
      • 7.3.4. Global Renal Anemia Therapeutics Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Renal Anemia Therapeutics (Price)
      • 7.4.1. Global Renal Anemia Therapeutics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Renal Anemia Therapeutics: by Type(USD Million)
  • Table 2. Renal Anemia Therapeutics DS-1093 , by Region USD Million (2013-2018)
  • Table 3. Renal Anemia Therapeutics EPO-018B , by Region USD Million (2013-2018)
  • Table 4. Renal Anemia Therapeutics FG-2216 , by Region USD Million (2013-2018)
  • Table 5. Renal Anemia Therapeutics JTZ-951 , by Region USD Million (2013-2018)
  • Table 6. Renal Anemia Therapeutics MDGN-201 , by Region USD Million (2013-2018)
  • Table 7. Renal Anemia Therapeutics: by Application(USD Million)
  • Table 8. Renal Anemia Therapeutics Hospital , by Region USD Million (2013-2018)
  • Table 9. Renal Anemia Therapeutics Research Center , by Region USD Million (2013-2018)
  • Table 10. Renal Anemia Therapeutics Clinic , by Region USD Million (2013-2018)
  • Table 11. Renal Anemia Therapeutics: by Mode of Administration(USD Million)
  • Table 12. Renal Anemia Therapeutics Oral , by Region USD Million (2013-2018)
  • Table 13. Renal Anemia Therapeutics Parenteral , by Region USD Million (2013-2018)
  • Table 14. South America Renal Anemia Therapeutics, by Country USD Million (2013-2018)
  • Table 15. South America Renal Anemia Therapeutics, by Type USD Million (2013-2018)
  • Table 16. South America Renal Anemia Therapeutics, by Application USD Million (2013-2018)
  • Table 17. South America Renal Anemia Therapeutics, by Mode of Administration USD Million (2013-2018)
  • Table 18. Brazil Renal Anemia Therapeutics, by Type USD Million (2013-2018)
  • Table 19. Brazil Renal Anemia Therapeutics, by Application USD Million (2013-2018)
  • Table 20. Brazil Renal Anemia Therapeutics, by Mode of Administration USD Million (2013-2018)
  • Table 21. Argentina Renal Anemia Therapeutics, by Type USD Million (2013-2018)
  • Table 22. Argentina Renal Anemia Therapeutics, by Application USD Million (2013-2018)
  • Table 23. Argentina Renal Anemia Therapeutics, by Mode of Administration USD Million (2013-2018)
  • Table 24. Rest of South America Renal Anemia Therapeutics, by Type USD Million (2013-2018)
  • Table 25. Rest of South America Renal Anemia Therapeutics, by Application USD Million (2013-2018)
  • Table 26. Rest of South America Renal Anemia Therapeutics, by Mode of Administration USD Million (2013-2018)
  • Table 27. Asia Pacific Renal Anemia Therapeutics, by Country USD Million (2013-2018)
  • Table 28. Asia Pacific Renal Anemia Therapeutics, by Type USD Million (2013-2018)
  • Table 29. Asia Pacific Renal Anemia Therapeutics, by Application USD Million (2013-2018)
  • Table 30. Asia Pacific Renal Anemia Therapeutics, by Mode of Administration USD Million (2013-2018)
  • Table 31. China Renal Anemia Therapeutics, by Type USD Million (2013-2018)
  • Table 32. China Renal Anemia Therapeutics, by Application USD Million (2013-2018)
  • Table 33. China Renal Anemia Therapeutics, by Mode of Administration USD Million (2013-2018)
  • Table 34. Japan Renal Anemia Therapeutics, by Type USD Million (2013-2018)
  • Table 35. Japan Renal Anemia Therapeutics, by Application USD Million (2013-2018)
  • Table 36. Japan Renal Anemia Therapeutics, by Mode of Administration USD Million (2013-2018)
  • Table 37. India Renal Anemia Therapeutics, by Type USD Million (2013-2018)
  • Table 38. India Renal Anemia Therapeutics, by Application USD Million (2013-2018)
  • Table 39. India Renal Anemia Therapeutics, by Mode of Administration USD Million (2013-2018)
  • Table 40. South Korea Renal Anemia Therapeutics, by Type USD Million (2013-2018)
  • Table 41. South Korea Renal Anemia Therapeutics, by Application USD Million (2013-2018)
  • Table 42. South Korea Renal Anemia Therapeutics, by Mode of Administration USD Million (2013-2018)
  • Table 43. Taiwan Renal Anemia Therapeutics, by Type USD Million (2013-2018)
  • Table 44. Taiwan Renal Anemia Therapeutics, by Application USD Million (2013-2018)
  • Table 45. Taiwan Renal Anemia Therapeutics, by Mode of Administration USD Million (2013-2018)
  • Table 46. Australia Renal Anemia Therapeutics, by Type USD Million (2013-2018)
  • Table 47. Australia Renal Anemia Therapeutics, by Application USD Million (2013-2018)
  • Table 48. Australia Renal Anemia Therapeutics, by Mode of Administration USD Million (2013-2018)
  • Table 49. Rest of Asia-Pacific Renal Anemia Therapeutics, by Type USD Million (2013-2018)
  • Table 50. Rest of Asia-Pacific Renal Anemia Therapeutics, by Application USD Million (2013-2018)
  • Table 51. Rest of Asia-Pacific Renal Anemia Therapeutics, by Mode of Administration USD Million (2013-2018)
  • Table 52. Europe Renal Anemia Therapeutics, by Country USD Million (2013-2018)
  • Table 53. Europe Renal Anemia Therapeutics, by Type USD Million (2013-2018)
  • Table 54. Europe Renal Anemia Therapeutics, by Application USD Million (2013-2018)
  • Table 55. Europe Renal Anemia Therapeutics, by Mode of Administration USD Million (2013-2018)
  • Table 56. Germany Renal Anemia Therapeutics, by Type USD Million (2013-2018)
  • Table 57. Germany Renal Anemia Therapeutics, by Application USD Million (2013-2018)
  • Table 58. Germany Renal Anemia Therapeutics, by Mode of Administration USD Million (2013-2018)
  • Table 59. France Renal Anemia Therapeutics, by Type USD Million (2013-2018)
  • Table 60. France Renal Anemia Therapeutics, by Application USD Million (2013-2018)
  • Table 61. France Renal Anemia Therapeutics, by Mode of Administration USD Million (2013-2018)
  • Table 62. Italy Renal Anemia Therapeutics, by Type USD Million (2013-2018)
  • Table 63. Italy Renal Anemia Therapeutics, by Application USD Million (2013-2018)
  • Table 64. Italy Renal Anemia Therapeutics, by Mode of Administration USD Million (2013-2018)
  • Table 65. United Kingdom Renal Anemia Therapeutics, by Type USD Million (2013-2018)
  • Table 66. United Kingdom Renal Anemia Therapeutics, by Application USD Million (2013-2018)
  • Table 67. United Kingdom Renal Anemia Therapeutics, by Mode of Administration USD Million (2013-2018)
  • Table 68. Netherlands Renal Anemia Therapeutics, by Type USD Million (2013-2018)
  • Table 69. Netherlands Renal Anemia Therapeutics, by Application USD Million (2013-2018)
  • Table 70. Netherlands Renal Anemia Therapeutics, by Mode of Administration USD Million (2013-2018)
  • Table 71. Rest of Europe Renal Anemia Therapeutics, by Type USD Million (2013-2018)
  • Table 72. Rest of Europe Renal Anemia Therapeutics, by Application USD Million (2013-2018)
  • Table 73. Rest of Europe Renal Anemia Therapeutics, by Mode of Administration USD Million (2013-2018)
  • Table 74. MEA Renal Anemia Therapeutics, by Country USD Million (2013-2018)
  • Table 75. MEA Renal Anemia Therapeutics, by Type USD Million (2013-2018)
  • Table 76. MEA Renal Anemia Therapeutics, by Application USD Million (2013-2018)
  • Table 77. MEA Renal Anemia Therapeutics, by Mode of Administration USD Million (2013-2018)
  • Table 78. Middle East Renal Anemia Therapeutics, by Type USD Million (2013-2018)
  • Table 79. Middle East Renal Anemia Therapeutics, by Application USD Million (2013-2018)
  • Table 80. Middle East Renal Anemia Therapeutics, by Mode of Administration USD Million (2013-2018)
  • Table 81. Africa Renal Anemia Therapeutics, by Type USD Million (2013-2018)
  • Table 82. Africa Renal Anemia Therapeutics, by Application USD Million (2013-2018)
  • Table 83. Africa Renal Anemia Therapeutics, by Mode of Administration USD Million (2013-2018)
  • Table 84. North America Renal Anemia Therapeutics, by Country USD Million (2013-2018)
  • Table 85. North America Renal Anemia Therapeutics, by Type USD Million (2013-2018)
  • Table 86. North America Renal Anemia Therapeutics, by Application USD Million (2013-2018)
  • Table 87. North America Renal Anemia Therapeutics, by Mode of Administration USD Million (2013-2018)
  • Table 88. United States Renal Anemia Therapeutics, by Type USD Million (2013-2018)
  • Table 89. United States Renal Anemia Therapeutics, by Application USD Million (2013-2018)
  • Table 90. United States Renal Anemia Therapeutics, by Mode of Administration USD Million (2013-2018)
  • Table 91. Canada Renal Anemia Therapeutics, by Type USD Million (2013-2018)
  • Table 92. Canada Renal Anemia Therapeutics, by Application USD Million (2013-2018)
  • Table 93. Canada Renal Anemia Therapeutics, by Mode of Administration USD Million (2013-2018)
  • Table 94. Mexico Renal Anemia Therapeutics, by Type USD Million (2013-2018)
  • Table 95. Mexico Renal Anemia Therapeutics, by Application USD Million (2013-2018)
  • Table 96. Mexico Renal Anemia Therapeutics, by Mode of Administration USD Million (2013-2018)
  • Table 97. Renal Anemia Therapeutics Sales: by Type(Unit)
  • Table 98. Renal Anemia Therapeutics Sales DS-1093 , by Region Unit (2013-2018)
  • Table 99. Renal Anemia Therapeutics Sales EPO-018B , by Region Unit (2013-2018)
  • Table 100. Renal Anemia Therapeutics Sales FG-2216 , by Region Unit (2013-2018)
  • Table 101. Renal Anemia Therapeutics Sales JTZ-951 , by Region Unit (2013-2018)
  • Table 102. Renal Anemia Therapeutics Sales MDGN-201 , by Region Unit (2013-2018)
  • Table 103. Renal Anemia Therapeutics Sales: by Application(Unit)
  • Table 104. Renal Anemia Therapeutics Sales Hospital , by Region Unit (2013-2018)
  • Table 105. Renal Anemia Therapeutics Sales Research Center , by Region Unit (2013-2018)
  • Table 106. Renal Anemia Therapeutics Sales Clinic , by Region Unit (2013-2018)
  • Table 107. Renal Anemia Therapeutics Sales: by Mode of Administration(Unit)
  • Table 108. Renal Anemia Therapeutics Sales Oral , by Region Unit (2013-2018)
  • Table 109. Renal Anemia Therapeutics Sales Parenteral , by Region Unit (2013-2018)
  • Table 110. South America Renal Anemia Therapeutics Sales, by Country Unit (2013-2018)
  • Table 111. South America Renal Anemia Therapeutics Sales, by Type Unit (2013-2018)
  • Table 112. South America Renal Anemia Therapeutics Sales, by Application Unit (2013-2018)
  • Table 113. South America Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2013-2018)
  • Table 114. Brazil Renal Anemia Therapeutics Sales, by Type Unit (2013-2018)
  • Table 115. Brazil Renal Anemia Therapeutics Sales, by Application Unit (2013-2018)
  • Table 116. Brazil Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2013-2018)
  • Table 117. Argentina Renal Anemia Therapeutics Sales, by Type Unit (2013-2018)
  • Table 118. Argentina Renal Anemia Therapeutics Sales, by Application Unit (2013-2018)
  • Table 119. Argentina Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2013-2018)
  • Table 120. Rest of South America Renal Anemia Therapeutics Sales, by Type Unit (2013-2018)
  • Table 121. Rest of South America Renal Anemia Therapeutics Sales, by Application Unit (2013-2018)
  • Table 122. Rest of South America Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2013-2018)
  • Table 123. Asia Pacific Renal Anemia Therapeutics Sales, by Country Unit (2013-2018)
  • Table 124. Asia Pacific Renal Anemia Therapeutics Sales, by Type Unit (2013-2018)
  • Table 125. Asia Pacific Renal Anemia Therapeutics Sales, by Application Unit (2013-2018)
  • Table 126. Asia Pacific Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2013-2018)
  • Table 127. China Renal Anemia Therapeutics Sales, by Type Unit (2013-2018)
  • Table 128. China Renal Anemia Therapeutics Sales, by Application Unit (2013-2018)
  • Table 129. China Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2013-2018)
  • Table 130. Japan Renal Anemia Therapeutics Sales, by Type Unit (2013-2018)
  • Table 131. Japan Renal Anemia Therapeutics Sales, by Application Unit (2013-2018)
  • Table 132. Japan Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2013-2018)
  • Table 133. India Renal Anemia Therapeutics Sales, by Type Unit (2013-2018)
  • Table 134. India Renal Anemia Therapeutics Sales, by Application Unit (2013-2018)
  • Table 135. India Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2013-2018)
  • Table 136. South Korea Renal Anemia Therapeutics Sales, by Type Unit (2013-2018)
  • Table 137. South Korea Renal Anemia Therapeutics Sales, by Application Unit (2013-2018)
  • Table 138. South Korea Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2013-2018)
  • Table 139. Taiwan Renal Anemia Therapeutics Sales, by Type Unit (2013-2018)
  • Table 140. Taiwan Renal Anemia Therapeutics Sales, by Application Unit (2013-2018)
  • Table 141. Taiwan Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2013-2018)
  • Table 142. Australia Renal Anemia Therapeutics Sales, by Type Unit (2013-2018)
  • Table 143. Australia Renal Anemia Therapeutics Sales, by Application Unit (2013-2018)
  • Table 144. Australia Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2013-2018)
  • Table 145. Rest of Asia-Pacific Renal Anemia Therapeutics Sales, by Type Unit (2013-2018)
  • Table 146. Rest of Asia-Pacific Renal Anemia Therapeutics Sales, by Application Unit (2013-2018)
  • Table 147. Rest of Asia-Pacific Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2013-2018)
  • Table 148. Europe Renal Anemia Therapeutics Sales, by Country Unit (2013-2018)
  • Table 149. Europe Renal Anemia Therapeutics Sales, by Type Unit (2013-2018)
  • Table 150. Europe Renal Anemia Therapeutics Sales, by Application Unit (2013-2018)
  • Table 151. Europe Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2013-2018)
  • Table 152. Germany Renal Anemia Therapeutics Sales, by Type Unit (2013-2018)
  • Table 153. Germany Renal Anemia Therapeutics Sales, by Application Unit (2013-2018)
  • Table 154. Germany Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2013-2018)
  • Table 155. France Renal Anemia Therapeutics Sales, by Type Unit (2013-2018)
  • Table 156. France Renal Anemia Therapeutics Sales, by Application Unit (2013-2018)
  • Table 157. France Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2013-2018)
  • Table 158. Italy Renal Anemia Therapeutics Sales, by Type Unit (2013-2018)
  • Table 159. Italy Renal Anemia Therapeutics Sales, by Application Unit (2013-2018)
  • Table 160. Italy Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2013-2018)
  • Table 161. United Kingdom Renal Anemia Therapeutics Sales, by Type Unit (2013-2018)
  • Table 162. United Kingdom Renal Anemia Therapeutics Sales, by Application Unit (2013-2018)
  • Table 163. United Kingdom Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2013-2018)
  • Table 164. Netherlands Renal Anemia Therapeutics Sales, by Type Unit (2013-2018)
  • Table 165. Netherlands Renal Anemia Therapeutics Sales, by Application Unit (2013-2018)
  • Table 166. Netherlands Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2013-2018)
  • Table 167. Rest of Europe Renal Anemia Therapeutics Sales, by Type Unit (2013-2018)
  • Table 168. Rest of Europe Renal Anemia Therapeutics Sales, by Application Unit (2013-2018)
  • Table 169. Rest of Europe Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2013-2018)
  • Table 170. MEA Renal Anemia Therapeutics Sales, by Country Unit (2013-2018)
  • Table 171. MEA Renal Anemia Therapeutics Sales, by Type Unit (2013-2018)
  • Table 172. MEA Renal Anemia Therapeutics Sales, by Application Unit (2013-2018)
  • Table 173. MEA Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2013-2018)
  • Table 174. Middle East Renal Anemia Therapeutics Sales, by Type Unit (2013-2018)
  • Table 175. Middle East Renal Anemia Therapeutics Sales, by Application Unit (2013-2018)
  • Table 176. Middle East Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2013-2018)
  • Table 177. Africa Renal Anemia Therapeutics Sales, by Type Unit (2013-2018)
  • Table 178. Africa Renal Anemia Therapeutics Sales, by Application Unit (2013-2018)
  • Table 179. Africa Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2013-2018)
  • Table 180. North America Renal Anemia Therapeutics Sales, by Country Unit (2013-2018)
  • Table 181. North America Renal Anemia Therapeutics Sales, by Type Unit (2013-2018)
  • Table 182. North America Renal Anemia Therapeutics Sales, by Application Unit (2013-2018)
  • Table 183. North America Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2013-2018)
  • Table 184. United States Renal Anemia Therapeutics Sales, by Type Unit (2013-2018)
  • Table 185. United States Renal Anemia Therapeutics Sales, by Application Unit (2013-2018)
  • Table 186. United States Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2013-2018)
  • Table 187. Canada Renal Anemia Therapeutics Sales, by Type Unit (2013-2018)
  • Table 188. Canada Renal Anemia Therapeutics Sales, by Application Unit (2013-2018)
  • Table 189. Canada Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2013-2018)
  • Table 190. Mexico Renal Anemia Therapeutics Sales, by Type Unit (2013-2018)
  • Table 191. Mexico Renal Anemia Therapeutics Sales, by Application Unit (2013-2018)
  • Table 192. Mexico Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2013-2018)
  • Table 193. Renal Anemia Therapeutics: by Type(USD/Units)
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Renal Anemia Therapeutics: by Type(USD Million)
  • Table 205. Renal Anemia Therapeutics DS-1093 , by Region USD Million (2019-2024)
  • Table 206. Renal Anemia Therapeutics EPO-018B , by Region USD Million (2019-2024)
  • Table 207. Renal Anemia Therapeutics FG-2216 , by Region USD Million (2019-2024)
  • Table 208. Renal Anemia Therapeutics JTZ-951 , by Region USD Million (2019-2024)
  • Table 209. Renal Anemia Therapeutics MDGN-201 , by Region USD Million (2019-2024)
  • Table 210. Renal Anemia Therapeutics: by Application(USD Million)
  • Table 211. Renal Anemia Therapeutics Hospital , by Region USD Million (2019-2024)
  • Table 212. Renal Anemia Therapeutics Research Center , by Region USD Million (2019-2024)
  • Table 213. Renal Anemia Therapeutics Clinic , by Region USD Million (2019-2024)
  • Table 214. Renal Anemia Therapeutics: by Mode of Administration(USD Million)
  • Table 215. Renal Anemia Therapeutics Oral , by Region USD Million (2019-2024)
  • Table 216. Renal Anemia Therapeutics Parenteral , by Region USD Million (2019-2024)
  • Table 217. South America Renal Anemia Therapeutics, by Country USD Million (2019-2024)
  • Table 218. South America Renal Anemia Therapeutics, by Type USD Million (2019-2024)
  • Table 219. South America Renal Anemia Therapeutics, by Application USD Million (2019-2024)
  • Table 220. South America Renal Anemia Therapeutics, by Mode of Administration USD Million (2019-2024)
  • Table 221. Brazil Renal Anemia Therapeutics, by Type USD Million (2019-2024)
  • Table 222. Brazil Renal Anemia Therapeutics, by Application USD Million (2019-2024)
  • Table 223. Brazil Renal Anemia Therapeutics, by Mode of Administration USD Million (2019-2024)
  • Table 224. Argentina Renal Anemia Therapeutics, by Type USD Million (2019-2024)
  • Table 225. Argentina Renal Anemia Therapeutics, by Application USD Million (2019-2024)
  • Table 226. Argentina Renal Anemia Therapeutics, by Mode of Administration USD Million (2019-2024)
  • Table 227. Rest of South America Renal Anemia Therapeutics, by Type USD Million (2019-2024)
  • Table 228. Rest of South America Renal Anemia Therapeutics, by Application USD Million (2019-2024)
  • Table 229. Rest of South America Renal Anemia Therapeutics, by Mode of Administration USD Million (2019-2024)
  • Table 230. Asia Pacific Renal Anemia Therapeutics, by Country USD Million (2019-2024)
  • Table 231. Asia Pacific Renal Anemia Therapeutics, by Type USD Million (2019-2024)
  • Table 232. Asia Pacific Renal Anemia Therapeutics, by Application USD Million (2019-2024)
  • Table 233. Asia Pacific Renal Anemia Therapeutics, by Mode of Administration USD Million (2019-2024)
  • Table 234. China Renal Anemia Therapeutics, by Type USD Million (2019-2024)
  • Table 235. China Renal Anemia Therapeutics, by Application USD Million (2019-2024)
  • Table 236. China Renal Anemia Therapeutics, by Mode of Administration USD Million (2019-2024)
  • Table 237. Japan Renal Anemia Therapeutics, by Type USD Million (2019-2024)
  • Table 238. Japan Renal Anemia Therapeutics, by Application USD Million (2019-2024)
  • Table 239. Japan Renal Anemia Therapeutics, by Mode of Administration USD Million (2019-2024)
  • Table 240. India Renal Anemia Therapeutics, by Type USD Million (2019-2024)
  • Table 241. India Renal Anemia Therapeutics, by Application USD Million (2019-2024)
  • Table 242. India Renal Anemia Therapeutics, by Mode of Administration USD Million (2019-2024)
  • Table 243. South Korea Renal Anemia Therapeutics, by Type USD Million (2019-2024)
  • Table 244. South Korea Renal Anemia Therapeutics, by Application USD Million (2019-2024)
  • Table 245. South Korea Renal Anemia Therapeutics, by Mode of Administration USD Million (2019-2024)
  • Table 246. Taiwan Renal Anemia Therapeutics, by Type USD Million (2019-2024)
  • Table 247. Taiwan Renal Anemia Therapeutics, by Application USD Million (2019-2024)
  • Table 248. Taiwan Renal Anemia Therapeutics, by Mode of Administration USD Million (2019-2024)
  • Table 249. Australia Renal Anemia Therapeutics, by Type USD Million (2019-2024)
  • Table 250. Australia Renal Anemia Therapeutics, by Application USD Million (2019-2024)
  • Table 251. Australia Renal Anemia Therapeutics, by Mode of Administration USD Million (2019-2024)
  • Table 252. Rest of Asia-Pacific Renal Anemia Therapeutics, by Type USD Million (2019-2024)
  • Table 253. Rest of Asia-Pacific Renal Anemia Therapeutics, by Application USD Million (2019-2024)
  • Table 254. Rest of Asia-Pacific Renal Anemia Therapeutics, by Mode of Administration USD Million (2019-2024)
  • Table 255. Europe Renal Anemia Therapeutics, by Country USD Million (2019-2024)
  • Table 256. Europe Renal Anemia Therapeutics, by Type USD Million (2019-2024)
  • Table 257. Europe Renal Anemia Therapeutics, by Application USD Million (2019-2024)
  • Table 258. Europe Renal Anemia Therapeutics, by Mode of Administration USD Million (2019-2024)
  • Table 259. Germany Renal Anemia Therapeutics, by Type USD Million (2019-2024)
  • Table 260. Germany Renal Anemia Therapeutics, by Application USD Million (2019-2024)
  • Table 261. Germany Renal Anemia Therapeutics, by Mode of Administration USD Million (2019-2024)
  • Table 262. France Renal Anemia Therapeutics, by Type USD Million (2019-2024)
  • Table 263. France Renal Anemia Therapeutics, by Application USD Million (2019-2024)
  • Table 264. France Renal Anemia Therapeutics, by Mode of Administration USD Million (2019-2024)
  • Table 265. Italy Renal Anemia Therapeutics, by Type USD Million (2019-2024)
  • Table 266. Italy Renal Anemia Therapeutics, by Application USD Million (2019-2024)
  • Table 267. Italy Renal Anemia Therapeutics, by Mode of Administration USD Million (2019-2024)
  • Table 268. United Kingdom Renal Anemia Therapeutics, by Type USD Million (2019-2024)
  • Table 269. United Kingdom Renal Anemia Therapeutics, by Application USD Million (2019-2024)
  • Table 270. United Kingdom Renal Anemia Therapeutics, by Mode of Administration USD Million (2019-2024)
  • Table 271. Netherlands Renal Anemia Therapeutics, by Type USD Million (2019-2024)
  • Table 272. Netherlands Renal Anemia Therapeutics, by Application USD Million (2019-2024)
  • Table 273. Netherlands Renal Anemia Therapeutics, by Mode of Administration USD Million (2019-2024)
  • Table 274. Rest of Europe Renal Anemia Therapeutics, by Type USD Million (2019-2024)
  • Table 275. Rest of Europe Renal Anemia Therapeutics, by Application USD Million (2019-2024)
  • Table 276. Rest of Europe Renal Anemia Therapeutics, by Mode of Administration USD Million (2019-2024)
  • Table 277. MEA Renal Anemia Therapeutics, by Country USD Million (2019-2024)
  • Table 278. MEA Renal Anemia Therapeutics, by Type USD Million (2019-2024)
  • Table 279. MEA Renal Anemia Therapeutics, by Application USD Million (2019-2024)
  • Table 280. MEA Renal Anemia Therapeutics, by Mode of Administration USD Million (2019-2024)
  • Table 281. Middle East Renal Anemia Therapeutics, by Type USD Million (2019-2024)
  • Table 282. Middle East Renal Anemia Therapeutics, by Application USD Million (2019-2024)
  • Table 283. Middle East Renal Anemia Therapeutics, by Mode of Administration USD Million (2019-2024)
  • Table 284. Africa Renal Anemia Therapeutics, by Type USD Million (2019-2024)
  • Table 285. Africa Renal Anemia Therapeutics, by Application USD Million (2019-2024)
  • Table 286. Africa Renal Anemia Therapeutics, by Mode of Administration USD Million (2019-2024)
  • Table 287. North America Renal Anemia Therapeutics, by Country USD Million (2019-2024)
  • Table 288. North America Renal Anemia Therapeutics, by Type USD Million (2019-2024)
  • Table 289. North America Renal Anemia Therapeutics, by Application USD Million (2019-2024)
  • Table 290. North America Renal Anemia Therapeutics, by Mode of Administration USD Million (2019-2024)
  • Table 291. United States Renal Anemia Therapeutics, by Type USD Million (2019-2024)
  • Table 292. United States Renal Anemia Therapeutics, by Application USD Million (2019-2024)
  • Table 293. United States Renal Anemia Therapeutics, by Mode of Administration USD Million (2019-2024)
  • Table 294. Canada Renal Anemia Therapeutics, by Type USD Million (2019-2024)
  • Table 295. Canada Renal Anemia Therapeutics, by Application USD Million (2019-2024)
  • Table 296. Canada Renal Anemia Therapeutics, by Mode of Administration USD Million (2019-2024)
  • Table 297. Mexico Renal Anemia Therapeutics, by Type USD Million (2019-2024)
  • Table 298. Mexico Renal Anemia Therapeutics, by Application USD Million (2019-2024)
  • Table 299. Mexico Renal Anemia Therapeutics, by Mode of Administration USD Million (2019-2024)
  • Table 300. Renal Anemia Therapeutics Sales: by Type(Unit)
  • Table 301. Renal Anemia Therapeutics Sales DS-1093 , by Region Unit (2019-2024)
  • Table 302. Renal Anemia Therapeutics Sales EPO-018B , by Region Unit (2019-2024)
  • Table 303. Renal Anemia Therapeutics Sales FG-2216 , by Region Unit (2019-2024)
  • Table 304. Renal Anemia Therapeutics Sales JTZ-951 , by Region Unit (2019-2024)
  • Table 305. Renal Anemia Therapeutics Sales MDGN-201 , by Region Unit (2019-2024)
  • Table 306. Renal Anemia Therapeutics Sales: by Application(Unit)
  • Table 307. Renal Anemia Therapeutics Sales Hospital , by Region Unit (2019-2024)
  • Table 308. Renal Anemia Therapeutics Sales Research Center , by Region Unit (2019-2024)
  • Table 309. Renal Anemia Therapeutics Sales Clinic , by Region Unit (2019-2024)
  • Table 310. Renal Anemia Therapeutics Sales: by Mode of Administration(Unit)
  • Table 311. Renal Anemia Therapeutics Sales Oral , by Region Unit (2019-2024)
  • Table 312. Renal Anemia Therapeutics Sales Parenteral , by Region Unit (2019-2024)
  • Table 313. South America Renal Anemia Therapeutics Sales, by Country Unit (2019-2024)
  • Table 314. South America Renal Anemia Therapeutics Sales, by Type Unit (2019-2024)
  • Table 315. South America Renal Anemia Therapeutics Sales, by Application Unit (2019-2024)
  • Table 316. South America Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2019-2024)
  • Table 317. Brazil Renal Anemia Therapeutics Sales, by Type Unit (2019-2024)
  • Table 318. Brazil Renal Anemia Therapeutics Sales, by Application Unit (2019-2024)
  • Table 319. Brazil Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2019-2024)
  • Table 320. Argentina Renal Anemia Therapeutics Sales, by Type Unit (2019-2024)
  • Table 321. Argentina Renal Anemia Therapeutics Sales, by Application Unit (2019-2024)
  • Table 322. Argentina Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2019-2024)
  • Table 323. Rest of South America Renal Anemia Therapeutics Sales, by Type Unit (2019-2024)
  • Table 324. Rest of South America Renal Anemia Therapeutics Sales, by Application Unit (2019-2024)
  • Table 325. Rest of South America Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2019-2024)
  • Table 326. Asia Pacific Renal Anemia Therapeutics Sales, by Country Unit (2019-2024)
  • Table 327. Asia Pacific Renal Anemia Therapeutics Sales, by Type Unit (2019-2024)
  • Table 328. Asia Pacific Renal Anemia Therapeutics Sales, by Application Unit (2019-2024)
  • Table 329. Asia Pacific Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2019-2024)
  • Table 330. China Renal Anemia Therapeutics Sales, by Type Unit (2019-2024)
  • Table 331. China Renal Anemia Therapeutics Sales, by Application Unit (2019-2024)
  • Table 332. China Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2019-2024)
  • Table 333. Japan Renal Anemia Therapeutics Sales, by Type Unit (2019-2024)
  • Table 334. Japan Renal Anemia Therapeutics Sales, by Application Unit (2019-2024)
  • Table 335. Japan Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2019-2024)
  • Table 336. India Renal Anemia Therapeutics Sales, by Type Unit (2019-2024)
  • Table 337. India Renal Anemia Therapeutics Sales, by Application Unit (2019-2024)
  • Table 338. India Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2019-2024)
  • Table 339. South Korea Renal Anemia Therapeutics Sales, by Type Unit (2019-2024)
  • Table 340. South Korea Renal Anemia Therapeutics Sales, by Application Unit (2019-2024)
  • Table 341. South Korea Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2019-2024)
  • Table 342. Taiwan Renal Anemia Therapeutics Sales, by Type Unit (2019-2024)
  • Table 343. Taiwan Renal Anemia Therapeutics Sales, by Application Unit (2019-2024)
  • Table 344. Taiwan Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2019-2024)
  • Table 345. Australia Renal Anemia Therapeutics Sales, by Type Unit (2019-2024)
  • Table 346. Australia Renal Anemia Therapeutics Sales, by Application Unit (2019-2024)
  • Table 347. Australia Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2019-2024)
  • Table 348. Rest of Asia-Pacific Renal Anemia Therapeutics Sales, by Type Unit (2019-2024)
  • Table 349. Rest of Asia-Pacific Renal Anemia Therapeutics Sales, by Application Unit (2019-2024)
  • Table 350. Rest of Asia-Pacific Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2019-2024)
  • Table 351. Europe Renal Anemia Therapeutics Sales, by Country Unit (2019-2024)
  • Table 352. Europe Renal Anemia Therapeutics Sales, by Type Unit (2019-2024)
  • Table 353. Europe Renal Anemia Therapeutics Sales, by Application Unit (2019-2024)
  • Table 354. Europe Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2019-2024)
  • Table 355. Germany Renal Anemia Therapeutics Sales, by Type Unit (2019-2024)
  • Table 356. Germany Renal Anemia Therapeutics Sales, by Application Unit (2019-2024)
  • Table 357. Germany Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2019-2024)
  • Table 358. France Renal Anemia Therapeutics Sales, by Type Unit (2019-2024)
  • Table 359. France Renal Anemia Therapeutics Sales, by Application Unit (2019-2024)
  • Table 360. France Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2019-2024)
  • Table 361. Italy Renal Anemia Therapeutics Sales, by Type Unit (2019-2024)
  • Table 362. Italy Renal Anemia Therapeutics Sales, by Application Unit (2019-2024)
  • Table 363. Italy Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2019-2024)
  • Table 364. United Kingdom Renal Anemia Therapeutics Sales, by Type Unit (2019-2024)
  • Table 365. United Kingdom Renal Anemia Therapeutics Sales, by Application Unit (2019-2024)
  • Table 366. United Kingdom Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2019-2024)
  • Table 367. Netherlands Renal Anemia Therapeutics Sales, by Type Unit (2019-2024)
  • Table 368. Netherlands Renal Anemia Therapeutics Sales, by Application Unit (2019-2024)
  • Table 369. Netherlands Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2019-2024)
  • Table 370. Rest of Europe Renal Anemia Therapeutics Sales, by Type Unit (2019-2024)
  • Table 371. Rest of Europe Renal Anemia Therapeutics Sales, by Application Unit (2019-2024)
  • Table 372. Rest of Europe Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2019-2024)
  • Table 373. MEA Renal Anemia Therapeutics Sales, by Country Unit (2019-2024)
  • Table 374. MEA Renal Anemia Therapeutics Sales, by Type Unit (2019-2024)
  • Table 375. MEA Renal Anemia Therapeutics Sales, by Application Unit (2019-2024)
  • Table 376. MEA Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2019-2024)
  • Table 377. Middle East Renal Anemia Therapeutics Sales, by Type Unit (2019-2024)
  • Table 378. Middle East Renal Anemia Therapeutics Sales, by Application Unit (2019-2024)
  • Table 379. Middle East Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2019-2024)
  • Table 380. Africa Renal Anemia Therapeutics Sales, by Type Unit (2019-2024)
  • Table 381. Africa Renal Anemia Therapeutics Sales, by Application Unit (2019-2024)
  • Table 382. Africa Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2019-2024)
  • Table 383. North America Renal Anemia Therapeutics Sales, by Country Unit (2019-2024)
  • Table 384. North America Renal Anemia Therapeutics Sales, by Type Unit (2019-2024)
  • Table 385. North America Renal Anemia Therapeutics Sales, by Application Unit (2019-2024)
  • Table 386. North America Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2019-2024)
  • Table 387. United States Renal Anemia Therapeutics Sales, by Type Unit (2019-2024)
  • Table 388. United States Renal Anemia Therapeutics Sales, by Application Unit (2019-2024)
  • Table 389. United States Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2019-2024)
  • Table 390. Canada Renal Anemia Therapeutics Sales, by Type Unit (2019-2024)
  • Table 391. Canada Renal Anemia Therapeutics Sales, by Application Unit (2019-2024)
  • Table 392. Canada Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2019-2024)
  • Table 393. Mexico Renal Anemia Therapeutics Sales, by Type Unit (2019-2024)
  • Table 394. Mexico Renal Anemia Therapeutics Sales, by Application Unit (2019-2024)
  • Table 395. Mexico Renal Anemia Therapeutics Sales, by Mode of Administration Unit (2019-2024)
  • Table 396. Renal Anemia Therapeutics: by Type(USD/Units)
  • Table 397. Research Programs/Design for This Report
  • Table 398. Key Data Information from Secondary Sources
  • Table 399. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Renal Anemia Therapeutics: by Type USD Million (2013-2018)
  • Figure 5. Global Renal Anemia Therapeutics: by Application USD Million (2013-2018)
  • Figure 6. Global Renal Anemia Therapeutics: by Mode of Administration USD Million (2013-2018)
  • Figure 7. South America Renal Anemia Therapeutics Share (%), by Country
  • Figure 8. Asia Pacific Renal Anemia Therapeutics Share (%), by Country
  • Figure 9. Europe Renal Anemia Therapeutics Share (%), by Country
  • Figure 10. MEA Renal Anemia Therapeutics Share (%), by Country
  • Figure 11. North America Renal Anemia Therapeutics Share (%), by Country
  • Figure 12. Global Renal Anemia Therapeutics: by Type Unit (2013-2018)
  • Figure 13. Global Renal Anemia Therapeutics: by Application Unit (2013-2018)
  • Figure 14. Global Renal Anemia Therapeutics: by Mode of Administration Unit (2013-2018)
  • Figure 15. South America Renal Anemia Therapeutics Share (%), by Country
  • Figure 16. Asia Pacific Renal Anemia Therapeutics Share (%), by Country
  • Figure 17. Europe Renal Anemia Therapeutics Share (%), by Country
  • Figure 18. MEA Renal Anemia Therapeutics Share (%), by Country
  • Figure 19. North America Renal Anemia Therapeutics Share (%), by Country
  • Figure 20. Global Renal Anemia Therapeutics: by Type USD/Units (2013-2018)
  • Figure 21. Global Renal Anemia Therapeutics share by Players 2018 (%)
  • Figure 22. Global Renal Anemia Therapeutics share by Players (Top 3) 2018(%)
  • Figure 23. Global Renal Anemia Therapeutics share by Players (Top 5) 2018(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 26. Bayer AG (Germany) Revenue: by Geography 2018
  • Figure 27. BIOCAD (Russia) Revenue, Net Income and Gross profit
  • Figure 28. BIOCAD (Russia) Revenue: by Geography 2018
  • Figure 29. CCM Duopharma Biotech Berhad (Malaysia) Revenue, Net Income and Gross profit
  • Figure 30. CCM Duopharma Biotech Berhad (Malaysia) Revenue: by Geography 2018
  • Figure 31. Chong Kun Dang Pharmaceutical Corp.(South Korea) Revenue, Net Income and Gross profit
  • Figure 32. Chong Kun Dang Pharmaceutical Corp.(South Korea) Revenue: by Geography 2018
  • Figure 33. Daiichi Sankyo Company, Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 34. Daiichi Sankyo Company, Limited (Japan) Revenue: by Geography 2018
  • Figure 35. Dong-A Socio Group (South Korea) Revenue, Net Income and Gross profit
  • Figure 36. Dong-A Socio Group (South Korea) Revenue: by Geography 2018
  • Figure 37. Dr. Reddy's Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 38. Dr. Reddy's Laboratories (India) Revenue: by Geography 2018
  • Figure 39. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 40. Eli Lilly and Company (United States) Revenue: by Geography 2018
  • Figure 41. FibroGen, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 42. FibroGen, Inc (United States) Revenue: by Geography 2018
  • Figure 43. GlaxoSmithKline Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 44. GlaxoSmithKline Plc (United Kingdom) Revenue: by Geography 2018
  • Figure 45. Global Renal Anemia Therapeutics: by Type USD Million (2019-2024)
  • Figure 46. Global Renal Anemia Therapeutics: by Application USD Million (2019-2024)
  • Figure 47. Global Renal Anemia Therapeutics: by Mode of Administration USD Million (2019-2024)
  • Figure 48. South America Renal Anemia Therapeutics Share (%), by Country
  • Figure 49. Asia Pacific Renal Anemia Therapeutics Share (%), by Country
  • Figure 50. Europe Renal Anemia Therapeutics Share (%), by Country
  • Figure 51. MEA Renal Anemia Therapeutics Share (%), by Country
  • Figure 52. North America Renal Anemia Therapeutics Share (%), by Country
  • Figure 53. Global Renal Anemia Therapeutics: by Type Unit (2019-2024)
  • Figure 54. Global Renal Anemia Therapeutics: by Application Unit (2019-2024)
  • Figure 55. Global Renal Anemia Therapeutics: by Mode of Administration Unit (2019-2024)
  • Figure 56. South America Renal Anemia Therapeutics Share (%), by Country
  • Figure 57. Asia Pacific Renal Anemia Therapeutics Share (%), by Country
  • Figure 58. Europe Renal Anemia Therapeutics Share (%), by Country
  • Figure 59. MEA Renal Anemia Therapeutics Share (%), by Country
  • Figure 60. North America Renal Anemia Therapeutics Share (%), by Country
  • Figure 61. Global Renal Anemia Therapeutics: by Type USD/Units (2019-2024)
List of companies from research coverage that are profiled in the study
  • Bayer AG (Germany)
  • BIOCAD (Russia)
  • CCM Duopharma Biotech Berhad (Malaysia)
  • Chong Kun Dang Pharmaceutical Corp.(South Korea)
  • Daiichi Sankyo Company, Limited (Japan)
  • Dong-A Socio Group (South Korea)
  • Dr. Reddy's Laboratories (India)
  • Eli Lilly and Company (United States)
  • FibroGen, Inc (United States)
  • GlaxoSmithKline Plc (United Kingdom)
Additional players considered in the study are as follows:
Intas Pharmaceuticals Ltd. (India) , JCR Pharmaceuticals Co., Ltd. (Japan) , Jiangsu Hansoh Pharmaceutical Co., Ltd.(China)
Select User Access Type

Key Highlights of Report


Dec 2019 225 Pages 75 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Renal Anemia Therapeutics Quantitative research analysis
Global Renal Anemia Therapeutics Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Renal Anemia Therapeutics Report?

Have a Query? Click Here

Other Related Reports

Antihemophilic Factor Comprehensive Study by Type (Plasma Derived, Plasma Derived/VWF Complex, Recombinant Antihemophilic Factor), Distribution (Hospital Pharmacies, Retail Pharmacies, Online Pharmac...
$ 3350
Sicca Syndrome Drug Comprehensive Study by Type (BMS-986142, Belimumab, Coversin, Filgotinib, LY-3090106, Others), Application (Hospital, Clinic, Others), Sales Channels (Online Sales Channel {Compan...
$ 3750
Hematological Malignancies Comprehensive Study by Type (Leukemia, Lymphoma, Myeloma), Route of Administration (Oral, Parenteral, Others), Distribution Channel (Hospitals, Retail Pharmacies, Online Ph...
$ 3650
Behavioral Therapy Comprehensive Study by Type (Cognitive behavioral therapy, Dialectical Behavior Therapy, Cognitive behavioral play therapy, System desensitization, Aversion therapy, Implosion ther...
$ 3750
Gene Therapy Comprehensive Study by Type (Somatic Cell Gene Therapy, Germ Cell Gene Therapy), Application (Neurological Disorders, Rare Diseases, Oncological Disorders, Cardiovascular Diseases, Infec...
$ 3450
Gallbladder Cancer Treatment Comprehensive Study by Type (Gemcitabine, Fluorouracil, Cisplatin, Oxaliplatin, Others (Binimetinib)), End User (Hospitals and Specialty Clinics, Cancer Research and Trea...
$ 3450